LNWWM
LH icon

Laird Norton Wetherby Wealth Management’s Labcorp LH Stock Holding History

Laird Norton Wetherby Wealth Management’s Portfolio LH Stock Details LH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$330K Buy
1,148
+60
+6% +$16.1K 0.01% 720
2025
Q2 		$286K Buy
+1,088
New +$265K 0.01% 747
2024
Q4 		$273K Sell
1,192
-87
-7% -$20K 0.01% 723
2024
Q3 		$286K Sell
1,279
-104
-8% -$22.9K 0.01% 748
2024
Q2 		$281K Buy
1,383
+15
+1% +$3.05K 0.01% 736
2024
Q1 		$299K Sell
1,368
-108
-7% -$23.8K 0.01% 744
2023
Q4 		$335K Buy
1,476
+52
+4% +$10.9K 0.02% 685
2023
Q3 		$286K Sell
1,424
-284
-17% -$59.9K 0.02% 699
2023
Q2 		$354K Sell
1,708
-95
-5% -$18.4K 0.02% 655
2023
Q1 		$355K Buy
1,803
+23
+1% +$4.73K 0.02% 651
2022
Q4 		$360K Buy
1,780
+107
+6% +$20.9K 0.02% 622
2022
Q3 		$294K Sell
1,673
-28
-2% -$5.73K 0.02% 664
2022
Q2 		$342K Buy
1,701
+31
+2% +$6.61K 0.02% 629
2022
Q1 		$378K Sell
1,670
-68
-4% -$16K 0.02% 612
2021
Q4 		$469K Buy
1,738
+51
+3% +$12.6K 0.03% 554
2021
Q3 		$408K Buy
1,687
+4
+0.2% +$1.01K 0.03% 577
2021
Q2 		$399K Sell
1,683
-245
-13% -$55.8K 0.02% 600
2021
Q1 		$422K Buy
1,928
+258
+15% +$51.8K 0.03% 495
2020
Q4 		$292K Buy
1,670
+114
+7% +$19.7K 0.02% 677
2020
Q3 		$252K Buy
1,556
+50
+3% +$7.92K 0.02% 571
2020
Q2 		$215K Buy
+1,506
New +$208K 0.02% 619
2020
Q1 		– Sell
-1,634
Closed -$238K – 723
2019
Q4 		$238K Sell
1,634
-89
-5% -$12.8K 0.02% 610
2019
Q3 		$249K Buy
1,723
+42
+2% +$6.13K 0.03% 602
2019
Q2 		$249K Buy
1,681
+127
+8% +$17.7K 0.03% 588
2019
Q1 		$204K Buy
+1,554
New +$191K 0.03% 616
2018
Q4 		– Sell
-1,773
Closed -$264K – 665
2018
Q3 		$264K Buy
1,773
+95
+6% +$14.4K 0.03% 540
2018
Q2 		$259K Sell
1,678
-91
-5% -$13.7K 0.04% 515
2018
Q1 		$246K Buy
1,769
+60
+4% +$8.81K 0.03% 535
2017
Q4 		$234K Buy
+1,709
New +$226K 0.03% 544

Other funds holding LH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Diamond Hill Capital Management
Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

Laird Norton Wetherby Wealth Management's LH Position: Q3 2025 in Review

Laird Norton Wetherby Wealth Management increased its Labcorp (LH) stake by 5.5% in Q3 2025, buying an estimated $16.1K and bringing the position to 1,148 shares worth $330K. The position accounts for 0.01% of the portfolio, ranked #720.

Laird Norton Wetherby Wealth Management first reported a position in LH in Q4 2017 and has held it in 29 quarters since. The position peaked at $469K in Q4 2021. 1,010 funds tracked by Wall St. Rank hold LH as of Q3 2025.

  • Laird Norton Wetherby Wealth Management held 1,148 shares of Labcorp worth $330K as of Q3 2025.
  • Laird Norton Wetherby Wealth Management bought 60 Labcorp shares in Q3 2025, an estimated $16.1K.
  • Labcorp made up 0.01% of Laird Norton Wetherby Wealth Management's portfolio in Q3 2025, its #720 holding.
  • Laird Norton Wetherby Wealth Management first reported a position in Labcorp in Q4 2017 and has held it in 29 quarters since.
  • Laird Norton Wetherby Wealth Management's Labcorp position peaked at $469K in Q4 2021.
  • 1,010 funds tracked by Wall St. Rank held Labcorp as of Q3 2025.

Based on Laird Norton Wetherby Wealth Management's 13F filing for Q3 2025, filed 14 Nov 2025.